Is BioLineRx Ltd. (BLRX) a Buy, Sell, or Hold?
NASDAQ : BLRX
BioLineRx Ltd. — Institutional Ownership
$2.745 USD
-$0.01 (-0.54%)
- Volume
- 2.19K
- Average Volume
- 48.78K
- Market Capitalization
- $11.94M
- P/E Ratio
- -1.39
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $4.56
- Year Low
- $2.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.58
Institutional Ownership Summary
Institutional Ownership %
%
Investors Holding
change: 0.0 | last:
Increased Positions
change: 0.0 | last:
Reduced Positions
change: 0.0 | last:
New Positions
change: 0.0 | last:
Sold Positions
change: 0.0 | last:
Total Calls
-
Total Puts
-
Put-Call Ratio
change: 0.0 | last:
Total Invested
-
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2025-08-14 | Highbridge Capital Management, LLC | 172.95M | 7.20% |
| 2025-01-10 | Mitchell P. Kopin | 102.24M | 4.99% |
| 2023-10-26 | Lepu (Hong Kong) Co., Limited | 102.44M | 9.50% |
| 2023-10-26 | Hong Seng Technology Limited | 102.44M | 9.50% |
| 2023-10-26 | Lepu Holdings Limited | 102.44M | 9.50% |
| 2023-10-26 | Lepu Medical Technology (Beijing) Co., Ltd. | 102.44M | 9.50% |
| 2023-10-26 | Lepu Medical (Europe) Cooperatief U.A. | 102.44M | 9.50% |
| 2022-02-11 | Mitchell P. Kopin | 7.43M | 1.00% |
| 2022-02-11 | Intracoastal Capital LLC | 7.43M | 1.00% |
| 2022-02-11 | Daniel B. Asher | 7.43M | 1.00% |
| 2021-02-16 | Novartis Pharma AG | 5M | 1.00% |
| 2021-02-16 | Novartis AG | 5M | 1.00% |
| 2021-02-16 | Altium Capital Growth GP, LLC | 18.01M | 3.70% |
| 2021-02-16 | Altium Capital Management, LP | 18.01M | 3.70% |
| 2021-02-12 | Senvest Management, LLC | 2.73M | 0.77% |
| 2021-02-16 | Altium Growth Fund, LP | 18.01M | 3.70% |
| 2020-06-05 | Armistice Capital, LLC | 1.04M | 4.99% |
| 2020-06-05 | Steven Boyd | 1.04M | 4.99% |
| 2020-06-05 | Armistice Capital Master Fund Ltd. | 1.04M | 4.99% |
| 2020-06-05 | The Capital Group Companies, Inc. | - | 0.00% |
| 2020-06-05 | Altium Capital Management, LP | 1.7M | 8.60% |
| 2020-06-05 | Altium Capital Growth GP, LLC | 1.7M | 8.60% |
| 2020-06-05 | Altium Growth Fund, LP | 1.7M | 8.60% |
| 2020-06-02 | Biotechnology Value Fund, L.P. | 14M | 5.30% |
| 2020-02-14 | BVF GP HOLDINGS LLC | 24.54M | 13.50% |
| 2020-02-14 | BVF Partners OS Ltd. | 2.66M | 1.50% |
| 2020-02-14 | Biotechnology Value Trading Fund OS LP | 2.66M | 1.50% |
| 2020-02-14 | BVF Partners L.P. | 31.94M | 17.50% |
| 2020-02-14 | Biotechnology Value Fund, L.P. | 14M | 7.80% |
| 2020-02-14 | Biotechnology Value Fund II, L.P. | 10.54M | 5.90% |
| 2020-02-14 | Mark N. Lampert | 31.94M | 17.50% |
| 2020-02-14 | BVF Inc. | 31.94M | 17.50% |
| 2020-02-14 | BVF II GP LLC | 10.54M | 5.90% |
| 2020-02-14 | BVF I GP LLC | 14M | 7.80% |
| 2020-02-07 | Richard Mashaal | 2.73M | 7.87% |
| 2020-02-07 | Senvest Management, LLC | 2.73M | 7.87% |
| 2019-02-08 | Richard Mashaal | 4.81M | 4.19% |
| 2019-02-08 | Richard Mashaal | 7.54M | 5.18% |
| 2019-02-08 | Senvest Management, LLC | 7.54M | 5.18% |
| 2019-02-08 | Senvest Management, LLC | 4.81M | 4.19% |
| 2018-02-12 | Richard Mashaal | 7.78M | 7.44% |
| 2018-02-12 | Senvest Management, LLC | 7.78M | 7.44% |
| 2017-12-14 | NOVARTIS PHARMA AG | 5M | 5.20% |
| 2017-12-14 | NOVARTIS AG | 5M | 5.20% |
| 2017-04-10 | BVF Partners OS Ltd. | 1.46M | 1.50% |
| 2017-04-10 | Biotechnology Value Fund, L.P. | 8.01M | 8.40% |
| 2017-04-10 | Biotechnology Value Trading Fund OS LP | 1.46M | 1.50% |
| 2017-04-10 | Mark N. Lampert | 17.5M | 18.30% |
| 2017-04-10 | BVF Inc. | 17.5M | 18.30% |
| 2017-04-10 | Biotechnology Value Fund II, L.P. | 5.24M | 5.50% |
| 2017-04-10 | BVF Partners L.P. | 17.5M | 18.30% |
| 2017-02-13 | Senvest Management, LLC | 349.65K | 9.01% |
| 2017-02-13 | Richard Mashaal | 349.65K | 9.01% |
| 2016-02-16 | OrbiMed Israel GP Ltd. | 2.64M | 4.69% |
| 2016-02-16 | OrbiMed Israel BioFund GP Limited Partnership | 2.64M | 4.69% |
| 2016-02-12 | Senvest Management, LLC | 3.95M | 7.23% |
| 2016-02-12 | Richard Mashaal | 3.95M | 7.23% |
| 2015-03-16 | Broadfin Capital, LLC | 31M | 6.00% |
| 2015-02-17 | OrbiMed Israel BioFund GP Limited Partnership | 27.35M | 7.70% |
| 2015-02-17 | OrbiMed Israel GP Ltd. | 27.35M | 7.70% |
| 2015-01-07 | Rima Senvest Management, L.L.C. | 26.29M | 6.70% |
| 2015-01-07 | Richard Mashaal | 26.29M | 6.70% |
| 2014-12-22 | NOVARTIS AG | 50M | 12.80% |
| 2014-12-22 | NOVARTIS PHARMA AG | 50M | 12.80% |
| 2014-02-13 | 9.99% (2) | 25.1M | 9.99% |
| 2014-02-13 | 9.99% (2) | 25.1M | 9.99% |
| 2013-02-19 | Rima Senvest Management, LLC | 7.4M | 4.03% |
| 2013-02-19 | Richard Mashaal | 7.4M | 4.03% |
| 2013-02-14 | Avraham Livnat | - | 0.00% |
| 2013-02-14 | Ruth Manor | - | 0.00% |
| 2013-02-14 | Clal Insurance Enterprises Holdings Ltd. | - | 0.00% |
| 2013-02-14 | IDB Development Corporation Ltd. | - | 0.00% |
| 2013-02-14 | IDB Holding Corporation Ltd. | - | 0.00% |
| 2013-02-14 | Nochi Dankner | - | 0.00% |
| 2013-02-14 | Shelly Bergman | - | 0.00% |
| 2012-03-29 | Migdal Insurance & Financial Holdings Ltd | 7.64M | 4.30% |
| 2012-03-20 | Richard Mashaal | 1.05M | 5.96% |
| 2012-03-20 | Rima Senvest Management, LLC | 1.05M | 5.96% |
| 2012-02-14 | Avraham Livnat | 10.68M | 8.64% |
| 2012-02-14 | Migdal Insurance & Financial Holdings Ltd | 7.64M | 6.18% |
| 2012-02-14 | Shelly Bergman | 10.68M | 8.64% |
| 2012-02-14 | IDB Development Corporation Ltd. | 10.68M | 8.64% |
| 2012-02-14 | Clal Insurance Enterprises Holdings Ltd. | 10.68M | 8.64% |
| 2012-02-14 | Nochi Dankner | 10.68M | 8.64% |
| 2012-02-14 | IDB Holding Corporation Ltd. | 10.68M | 8.64% |
| 2012-02-14 | IDB Development Corporation Ltd. | 10.68M | 8.64% |
| 2012-02-14 | Nochi Dankner | 10.68M | 8.64% |
| 2012-02-14 | Shelly Bergman | 10.68M | 8.64% |
| 2012-02-14 | Ruth Manor | 10.68M | 8.64% |
| 2012-02-14 | Avraham Livnat | 10.68M | 8.64% |
| 2012-02-14 | Clal Insurance Enterprises Holdings Ltd. | 10.68M | 8.64% |
| 2012-02-14 | IDB Holding Corporation Ltd. | 10.68M | 8.64% |
| 2012-02-14 | Ruth Manor | 10.68M | 8.64% |
BLRX Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $2.77 | 4.11M | $11.38M | $3.25M | $10.15M | $18.28M |
| 2024-12-31 | $8.56 | 2M | $17.09M | $10.44M | $15.04M | $21.7M |
| 2023-12-31 | $62.80 | 1.61M | $100.83M | $4.26M | $11.59M | $108.17M |
| 2022-12-31 | $23.60 | 1.29M | $30.44M | $10.59M | $12.32M | $32.18M |
| 2021-12-31 | $81.60 | 1.1M | $90.16M | $12.99M | $4.65M | $81.82M |
| 2020-12-31 | $100.80 | 421.41K | $42.48M | $16.83M | $7.68M | $33.33M |
| 2019-12-31 | $90.00 | 244.01K | $21.96M | $5.3M | $10.46M | $27.12M |
| 2018-12-31 | $262.38 | 180.99K | $47.49M | $3.4M | $8.73M | $52.82M |
| 2017-12-31 | $660.00 | 149.95K | $98.97M | $5.11M | $250K | $94.11M |
| 2016-12-31 | $552.00 | 93574 | $51.65M | $2.47M | $343K | $49.53M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2.30 | 4.43M | $10.2M | $2.5M | $9.07M | $16.76M |
| 2025-12-31 | $2.77 | 4.35M | $12.05M | $3.25M | $10.15M | $18.95M |
| 2025-09-30 | $3.78 | 3.95M | $14.93M | $7.91M | $11.38M | $18.39M |
| 2025-06-30 | $4.57 | 3.95M | $18.05M | $7.19M | $12.6M | $23.46M |
| 2025-03-31 | $2.96 | 2M | $5.91M | $9.04M | $13.74M | $10.62M |
| 2024-12-31 | $8.56 | 2M | $17.09M | $10.44M | $15.04M | $21.69M |
| 2024-09-30 | $21.44 | 2M | $42.8M | $8.84M | $29.61M | $63.58M |
| 2024-06-30 | $22.40 | 2M | $44.71M | $9.62M | $31.26M | $66.34M |
| 2024-03-31 | $34.41 | 1.81M | $62.32M | $5.99M | $11.31M | $67.64M |
| 2023-12-31 | $62.80 | 1.8M | $112.88M | $4.26M | $11.59M | $120.21M |
| 2023-09-30 | $72.80 | 1.55M | $112.73M | $7.73M | $13.31M | $118.31M |
| 2023-06-30 | $63.80 | 1.54M | $98.14M | $10.1M | $13.54M | $101.57M |